When does Perjeta go off patent?
In the US, biosimilars can launch from 2026. Perjeta is sold by Roche. Roche says its primary US and EU patents expired in Q2 2025 and expects the first biosimilars in 2026. Sales CHF 2.97B, down 13% as patients move to Phesgo, which combines Perjeta and Herceptin in one injection.
Perjeta's US exclusivity date is based on company guidance. The date comes from the company's own filings or guidance. Secondary patents, new formulations or litigation can still move it. It is a biologic, so copies are biosimilars. Biosimilars are harder to make and usually erode sales more gradually than generics.
Approved, waiting to launch The FDA approved Henlius and Organon's Poherdy as an interchangeable biosimilar in November 2025. Genentech's patent suit was settled in January 2026 on confidential terms, and no US launch has been announced.
Checked October 2026. Sources: Organon press release · Pearce IP: settlement
Company guidance. Roche says its primary US and EU patents expired in Q2 2025 and expects the first biosimilars in 2026. Sales CHF 2.97B, down 13% as patients move to Phesgo, which combines Perjeta and Herceptin in one injection.
Among past biologics facing biosimilars: Humira's US sales fell to 65% of their 2022 level in its first full year of biosimilars (2023) and 16% two years later; Stelara's US sales fell to 57% of their 2024 level in its first full year of biosimilars (2025). See how past cliffs played out →
Perjeta is 4.8% of Roche's 2025 revenue (≈$3.6B of $74.1B). With Xolair, Tecentriq, Ocrevus and Vabysmo, the drugs tracked here add up to 34% of Roche's revenue losing US exclusivity by 2034. Group sales CHF 61.5B, including Diagnostics.
Bars show each company's tracked drugs as a share of its total 2025 revenue. Perjeta is highlighted.